Upstream Bio (UPB) Stock: Buy, Sell, or Hold?
UPB - Upstream Bio, Inc. Common Stock
$5.73
-0.02 (-0.35%)
▼
5d:
-5.76%
30d:
-17.08%
90d:
-10.19%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When UPB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: UPB shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: UPB shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: UPB is currently trading at $5.73, which is considered oversold relative to its 30-day fair value range of $6.41 to $7.18.
Technical Outlook: Technically, UPB is in a strong downtrend. The price is currently testing key support at $5.65. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: UPB scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $31.14 (+443.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, UPB is in a strong downtrend. The price is currently testing key support at $5.65. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: UPB scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $31.14 (+443.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$6.41 -
$7.18
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 443.5% below Wall St target ($31.14)
- WARNING: Composite score 43/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$6.41 -
$7.18
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$5.65
Resistance Level
$6.98
Current Trend
Strong Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.05
Wall Street Target
$31.14
(+443.5%)
Revenue Growth (YoY)
-17.5%
Share & Embed Analysis
Last updated: September 13, 2026 7:45 AM ET
Data refreshes hourly during market hours. Next update: 8:45 AM
Data refreshes hourly during market hours. Next update: 8:45 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is UPB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 54 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 44 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 53 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 48 HOLD |
